Clinical Efficacy Study of Sanbai San in Treating Patients with Acute Lymphangitis

XIAO Xiaoyi; YANG Hengli

doi:10.14033/j.cnki.cfmr.2025.15.004

Abstract：Objective:To explore the clinical efficacy of Sanbai San in treating patients with acute lymphangitis.Method:65 patients with acute lymphangitis admitted to Jiangle General Hospital of Fujian Province from July 2023 to July 2024 were selected as the study objects,and were divided into control group(n=33)and experimental group(n=32)by random number table method.The control group received routine anti-infection treatment,and the experimental group was treated with Sanbai San on the basis of the control group.The postoperative efficacy,symptom improvement(skin color,skin temperature,swelling and pain degree),inflammatory factors[white blood cell count(WBC),C-reactive protein(CRP),procalcitonin(PCT)]and adverse reactions of the two groups were compared.Result:After treatment,the total effective rate of the experimental group was higher than that of the control group,and the scores of skin color,skin temperature,swelling and pain were significantly reduced,with statistical significance(P<0.05).After treatment,CRP,WBC and PCT levels in the experimental group were significantly lower than those in the control group,with statistical significance(P<0.05).During treatment,no adverse reactions occurred in both groups.Conclusion:Sanbai Powder is effective in patients with acute lymphangitis,can effectively improve clinical symptoms,inhibit inflammatory response,and has good safety.